This article was originally published in The Rose Sheet
Firm announces preliminary plans to relocate 350 consumer health care and animal care employees to new Summit, N.J. campus. The move is expected to be complete by year-end, Schering-Plough states. The site will be used for both office space and R&D operations and eventually will house approximately 1,700 employees, according to the company. "We plan to develop Summit into Schering-Plough's second-largest campus in New Jersey," next to the firm's Kenilworth headquarters, CEO Fred Hassan says. Satellite offices that may be affected by the move include a leased facility in Berkeley Heights, where the consumer health care business is located, two leased offices in Cranford and company-owned buildings in Madison, Springfield and Union. The project is not expected to result in any lay-offs, the firm adds...
You may also be interested in...
Formycon’s CEO has offered the latest indication that the coronavirus outbreak could provide a tailwind for biosimilars, as the firm gave an update on its biosimilars pipeline – including ranibizumab, ustekinumab, aflibercept and an undisclosed molecule, as well as other unrevealed projects – and how it has been affected by the pandemic.
With the formal, virtual kick-off meeting set for 23 July, US FDA and sponsors are looking at a transformed landscape as they discuss what the next five years of user fees will look like.
Keeping Track: Approvals For Phexxi, Kynombi; New Claims For Lynparza, Alunbrig, Tecentriq; Intercept May Miss NASH User Fee Date
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.